Module

Role of HBV DNA in Patient Management

Source: Clinical Strategies for Preventing and Managing Resistance to Anti-HBV Agents

Role of HBV DNA in Patient Management

Faculty:
Geoffrey M. Dusheiko, MD, FCP(SA), FRCP

CME CREDIT INFORMATION

Release Date: 04/14/06

Expiration Date: 04/13/07

Physicians: maximum of 1.0 AMA PRA Category 1 Credit(s)™

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Discuss HBV serologic markers in terms of the natural history of hepatitis B and disease stage
Review prognostic factors relating to hepatitis B disease severity and progression
Discuss the development of HBV drug resistance

Topics covered include:

Introduction
Serologic Markers of Chronic Hepatitis B
Predicting Disease Severity
Predicting Disease Outcomes
Clinical Assessment of HBV DNA in Chronic HBV Infection
HBV DNA Levels and Resistance
HBV Treatment

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.